Rx00084 - Difluprednate


Name:
Difluprednate
Rx ID:
Rx00084
Validation Level:
Phenomic Similarity:
0.693
Reference ID:
DB06781
Primary Indications:
Endogenous anterior uveitis; traumatic anterior uveitis; panuveitis
Orphan Indications:
No annotated orphan indications.
Rare Indications:
No annotated rare indications.
Common Indications:
Inflammation; pain
Pathways:
Serotonin Receptor 4-6-7 and NR3C Signaling; Regulation of Androgen receptor activity
Drug Interactions:
Bromfenac; Diclofenac; Flurbiprofen; Ketorolac Nepafenac;
Food Interactions:
No annotated food interactions in DrugBank.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00084
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
traumatic anterior uveitis pain 226 2723 35768 9.363 1.03E-130 3.3e-127
endogenous anterior uveitis pain 226 2723 35768 9.363 1.03E-130 3.3e-127

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
PANUVEITIS INFLAMMATION 9.11e-49 1231, 3807, 6775098, ABCB1, ABO, ACE, APOE, ARMS2, C4A, C4B, CASP1, CCL2, CCL5, CCR1, CCR3, CCR5, CCR6, CD14, CD28, CD40, CFB, CFH, CFI, CPB2, CTLA4, CXCR1, CXCR2, CYP1A1, CYP24A1, CYP27B1, CYP2C19, CYP2C9, CYP2R1, DARC, DEFA1, DEFB4A, DHCR7, ERAP1, F2, F5, FCGR2A, FCGR3A, FCGR3B, FCN2, FCRL3, GSTM1, GSTT1, HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-E, HLA-G, HTRA1, ICAM1, ICOSLG, IFNA1, IFNAR1, IFNAR2, IFNG, IL10, IL12A, IL12B, IL12RB2, IL13, IL17A, IL17F, IL18, IL18R1, IL19, IL1A, IL1B, IL1R1, IL1RN, IL2, IL23R, IL27, IL2RA, IL4, IL4R, IL6, IL6R, IL7R, IL8, IRF1, IRF5, ITGA2, ITGB3, JAK1, JAK2, KIAA1109, KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DP1, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, KIR3DS1, KLRC1, KLRC2, KLRC4, KLRK1, LEP, LTA, MBL2, MEFV, MICA, MICA, MICB, MIF, MIR146A, MIR196A2, MIR27A, MMP12, MMP2, MMP9, MPO, MTHFR, MVK, NAT2, NFKB1, NFKBIA, NLRP3, NOD2, NOS2, NOS3, OPN1LW, P2RX7, PDCD1, PON1, PROCR, PROZ, PSORS1C1, PSTPIP1, PTPN2, PTPN22, PYCARD, ROCK1, ROCK2, RUNX1, SERPINE1, SERPING1, SLC11A1, SLC22A4, SLC22A5, SOD2, SOD3, SPP1, STAT3, STAT4, SUMO4, TAP1, TAP2, TGFB1, TGFBR1, TGFBR3, TIMP2, TIRAP, TLR2, TLR4, TLR7, TLR8, TLR9, TNF, TNFAIP3, TNFRSF1A, TNFRSF1B, TNIP1, TRAF3IP2, TRAF5, TREM1, TYK2, TYMS, UTS2, VDR, VEGFA, VKORC1

Chemical, Pharmacological and Biological Annotations


ATC Code:
D07AC19
Categories:
Anti-Inflammatory Agents; Glucocorticoids; Corticosteroids
PubChem ID:
443936
KEGG Drug ID:
D01266
SMILE:
[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
InChI:
1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1
Classification:
Kingdom:
Organic Compounds
Superclass:
Lipids
Class:
Steroids and Steroid Derivatives
Subclass:
Gluco/mineralocorticoids, Progestogins and Derivatives
Indication:
For the treatment of inflammation and pain associated with ocular surgery.
Pharmacodynamics:
Difluprednate is a corticosteroid used as an anti-inflammatory steroidal drug used primarily in ocular surgery.
Description:
Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. Difluprednate is abbreviated DFBA, or difluoro...
Click to show more...
Mechanism:
Corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). It is postulated that these proteins control the biosynthesis of potent mediators of infammation such as prostaglandins and leukotrie...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
+
Caco-2 permeable:
+
P-glycoprotein substrate:
Substrate
P-glycoprotein inhibitor I:
Inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
2.1368 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org